Gentamicin-intercalated smectite as a new therapeutic option for Helicobacter pylori eradication

Su Jin Jeong, Jie Hyun Kim, Da Hyun Jung, Kyoung Hwa Lee, Soon Young Park, Yungoo Song, Il Mo Kang, Young Goo Song

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: Novel antibacterial strategies against Helicobacter pylori are needed because H. pylori strains are acquiring resistance to antibiotics. We evaluated the efficacy of gentamicin-intercalated smectite hybrid (S-GEN)-based treatment regimens in amurine model of H. pylori infection. Methods: Two groups of 10 rats were administered either smectite or S-GEN to measure coverage of the gastric mucosa. To evaluate anti-H. pylori efficacy, mice were divided into eight groups of 10 mice each given different treatments, and H. pylori eradication was assessed by a Campylobacter-like organism(CLO) test and H. pylori PCR of the gastric mucosa, and H. pylori antigen and H. pylori PCR analysis of mouse faeces. The levels of proinflammatory cytokines were examined. Results: S-GEN was retained in the gastric mucosal layer with a > 60% distribution ratio for up to 1 h, and the S-GEN-based triple regimen decreased bacterial burden in vivo compared with that of untreated mice or mice treated with other regimens. The cure rates in the CLO test and H. pylori PCR from gastric mucosa were 70%, 60%, 80%, 50%, 60% and 60% in Groups III-VIII, respectively. Those for H. pylori PCR in the faeces of mice were 90% and 100% in Group III with standard therapy and Group V with triple therapy including S-GEN, respectively. S-GEN triple therapy also reduced the levels of proinflammatory cytokines. Conclusions: These results suggest that S-GEN is a promising and effective therapeutic agent for the treatment of H. pylori infection.

Original languageEnglish
Pages (from-to)1324-1329
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume73
Issue number5
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Gentamicins
Helicobacter pylori
Gastric Mucosa
Therapeutics
Polymerase Chain Reaction
Campylobacter
Helicobacter Infections
Feces
Smectite
Cytokines
Microbial Drug Resistance
Group Psychotherapy
Stomach

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Jeong, Su Jin ; Kim, Jie Hyun ; Jung, Da Hyun ; Lee, Kyoung Hwa ; Park, Soon Young ; Song, Yungoo ; Kang, Il Mo ; Song, Young Goo. / Gentamicin-intercalated smectite as a new therapeutic option for Helicobacter pylori eradication. In: Journal of Antimicrobial Chemotherapy. 2018 ; Vol. 73, No. 5. pp. 1324-1329.
@article{458b8173f9104805afba163d506f3303,
title = "Gentamicin-intercalated smectite as a new therapeutic option for Helicobacter pylori eradication",
abstract = "Objectives: Novel antibacterial strategies against Helicobacter pylori are needed because H. pylori strains are acquiring resistance to antibiotics. We evaluated the efficacy of gentamicin-intercalated smectite hybrid (S-GEN)-based treatment regimens in amurine model of H. pylori infection. Methods: Two groups of 10 rats were administered either smectite or S-GEN to measure coverage of the gastric mucosa. To evaluate anti-H. pylori efficacy, mice were divided into eight groups of 10 mice each given different treatments, and H. pylori eradication was assessed by a Campylobacter-like organism(CLO) test and H. pylori PCR of the gastric mucosa, and H. pylori antigen and H. pylori PCR analysis of mouse faeces. The levels of proinflammatory cytokines were examined. Results: S-GEN was retained in the gastric mucosal layer with a > 60{\%} distribution ratio for up to 1 h, and the S-GEN-based triple regimen decreased bacterial burden in vivo compared with that of untreated mice or mice treated with other regimens. The cure rates in the CLO test and H. pylori PCR from gastric mucosa were 70{\%}, 60{\%}, 80{\%}, 50{\%}, 60{\%} and 60{\%} in Groups III-VIII, respectively. Those for H. pylori PCR in the faeces of mice were 90{\%} and 100{\%} in Group III with standard therapy and Group V with triple therapy including S-GEN, respectively. S-GEN triple therapy also reduced the levels of proinflammatory cytokines. Conclusions: These results suggest that S-GEN is a promising and effective therapeutic agent for the treatment of H. pylori infection.",
author = "Jeong, {Su Jin} and Kim, {Jie Hyun} and Jung, {Da Hyun} and Lee, {Kyoung Hwa} and Park, {Soon Young} and Yungoo Song and Kang, {Il Mo} and Song, {Young Goo}",
year = "2018",
month = "5",
day = "1",
doi = "10.1093/jac/dky011",
language = "English",
volume = "73",
pages = "1324--1329",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

Gentamicin-intercalated smectite as a new therapeutic option for Helicobacter pylori eradication. / Jeong, Su Jin; Kim, Jie Hyun; Jung, Da Hyun; Lee, Kyoung Hwa; Park, Soon Young; Song, Yungoo; Kang, Il Mo; Song, Young Goo.

In: Journal of Antimicrobial Chemotherapy, Vol. 73, No. 5, 01.05.2018, p. 1324-1329.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gentamicin-intercalated smectite as a new therapeutic option for Helicobacter pylori eradication

AU - Jeong, Su Jin

AU - Kim, Jie Hyun

AU - Jung, Da Hyun

AU - Lee, Kyoung Hwa

AU - Park, Soon Young

AU - Song, Yungoo

AU - Kang, Il Mo

AU - Song, Young Goo

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Objectives: Novel antibacterial strategies against Helicobacter pylori are needed because H. pylori strains are acquiring resistance to antibiotics. We evaluated the efficacy of gentamicin-intercalated smectite hybrid (S-GEN)-based treatment regimens in amurine model of H. pylori infection. Methods: Two groups of 10 rats were administered either smectite or S-GEN to measure coverage of the gastric mucosa. To evaluate anti-H. pylori efficacy, mice were divided into eight groups of 10 mice each given different treatments, and H. pylori eradication was assessed by a Campylobacter-like organism(CLO) test and H. pylori PCR of the gastric mucosa, and H. pylori antigen and H. pylori PCR analysis of mouse faeces. The levels of proinflammatory cytokines were examined. Results: S-GEN was retained in the gastric mucosal layer with a > 60% distribution ratio for up to 1 h, and the S-GEN-based triple regimen decreased bacterial burden in vivo compared with that of untreated mice or mice treated with other regimens. The cure rates in the CLO test and H. pylori PCR from gastric mucosa were 70%, 60%, 80%, 50%, 60% and 60% in Groups III-VIII, respectively. Those for H. pylori PCR in the faeces of mice were 90% and 100% in Group III with standard therapy and Group V with triple therapy including S-GEN, respectively. S-GEN triple therapy also reduced the levels of proinflammatory cytokines. Conclusions: These results suggest that S-GEN is a promising and effective therapeutic agent for the treatment of H. pylori infection.

AB - Objectives: Novel antibacterial strategies against Helicobacter pylori are needed because H. pylori strains are acquiring resistance to antibiotics. We evaluated the efficacy of gentamicin-intercalated smectite hybrid (S-GEN)-based treatment regimens in amurine model of H. pylori infection. Methods: Two groups of 10 rats were administered either smectite or S-GEN to measure coverage of the gastric mucosa. To evaluate anti-H. pylori efficacy, mice were divided into eight groups of 10 mice each given different treatments, and H. pylori eradication was assessed by a Campylobacter-like organism(CLO) test and H. pylori PCR of the gastric mucosa, and H. pylori antigen and H. pylori PCR analysis of mouse faeces. The levels of proinflammatory cytokines were examined. Results: S-GEN was retained in the gastric mucosal layer with a > 60% distribution ratio for up to 1 h, and the S-GEN-based triple regimen decreased bacterial burden in vivo compared with that of untreated mice or mice treated with other regimens. The cure rates in the CLO test and H. pylori PCR from gastric mucosa were 70%, 60%, 80%, 50%, 60% and 60% in Groups III-VIII, respectively. Those for H. pylori PCR in the faeces of mice were 90% and 100% in Group III with standard therapy and Group V with triple therapy including S-GEN, respectively. S-GEN triple therapy also reduced the levels of proinflammatory cytokines. Conclusions: These results suggest that S-GEN is a promising and effective therapeutic agent for the treatment of H. pylori infection.

UR - http://www.scopus.com/inward/record.url?scp=85047020464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047020464&partnerID=8YFLogxK

U2 - 10.1093/jac/dky011

DO - 10.1093/jac/dky011

M3 - Article

C2 - 29444284

AN - SCOPUS:85047020464

VL - 73

SP - 1324

EP - 1329

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

ER -